Thank you for joining the webinar!

We are admitting audience members from the waiting room.

Please allow a few moments for the webinar to begin.



HEALEY ALS Platform Trial

Community Q&A – July 24, 2025







Healey & AMG Center

Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital




















































Partnership, progress, and pathways forward



Thank You






Sharing our learnings

Operational Development and Launch of an Adaptive Platform Trial in Amyotrophic Lateral Sclerosis: Processes and Learnings From the First Four Regimens of the HEALEY ALS Platform Trial

First published: 26 May 2025

Open Access





https://onlinelibrary.wiley.com/doi/10.1002/mus.28442

Partnership, progress, and pathways forward

"Nothing about us without us"

Acknowledgments

This investigation was supported by philanthropic gifts to the Sean M. Healey and AMG Center for ALS and partially supported by Tackle ALS, ALS Finding a Cure, The ALS Association, ALS ONE, The Arthur M. Blank Family Foundation, and the Muscular Dystrophy Association. UCB, Biohaven Pharmaceuticals Inc., Clene Nanomedicine, and Prilenia Therapeutics provided investigational product and partially supported their individual regimen. We acknowledge the altruism of the participants and their families and contributions of the HEALEY ALS Platform Trial research and support staff at each of the participating sites for their contributions to this study. We are grateful for the formative input we received from all members of the HEALEY ALS Platform Trial Patient Advisory Committee and the Recruitment and Retention Committee, past and present. Additionally, we sincerely appreciate Raina Chrobak, MS, for creating the dynamic YouTube Studio dashboard used to track webinar views, and the members of the Data and Safety Monitoring Board (DSMB) (Jason Connor, PhD; Borje Darpo, MD, PhD FESC; Karl Kieburtz, MD, MPH; Ruth Schneider, MD; and Andrew Siderowf, MD) for their oversight and guidance in ensuring the integrity and safety of the trial.

TABLE 3 | Community and site engagement outcomes for the first four regimens.

Engagement strategy	Description of strategy	Engagement outcomes ^a
Introduction of patient navigator role	Patient Navigator served as a central resource to answer questions about the trial, develop educational resources, update website content, guide families through the trial enrollment process, and connect interested patients with local research centers. The Patient Navigator served as a member of the Recruitment and Retention Committee to seek patient feedback during monthly virtual meetings.	2,477 total emails/phone calls/zoom meetings with ALS families
		39 Countries in contact
		8 Webpages maintained
		103 Trial-related videos uploaded to YouTub
		4 Digital brochures created
		1 Email response template created
Site support surveys	REDCap surveys were sent to all participating Platform Trial research centers to collect information about site-specific enrollment policies, with a particular focus on understanding variable COVID-19 restrictions across institutions. Survey responses were collected by the Patient Navigator to guide prospective research participants to appropriate local site options and provide individualized site support as needed.	3 Surveys conducted between November 2020–March 2021
		41 Sites responded to each survey on average (79% of sites responded on average)
		16 Sites reported that they could only enroll participants from within their own clinic
		11 Sites reported that they could not enroll participants who lived out of state (due to COVID-19 restrictions)
Weekly Q&A webinars	Central leadership, in collaboration with the Patient Navigator, hosted a public webinar each week to provide trial updates and answer questions from the community. Special topic webinars, such as the regimen-specific drug science and mechanism of action webinars, were offered to address frequently asked questions. Recordings of each webinar were posted on YouTube and the Massachusetts General Hospital Platform Trial website.	102 Total webinars hosted
		72 Weekly attendees on average
		62 Guest speakers featured
		1,871 Questions answered live
		34,891 Total subsequent views on YouTube
Online eligibility checking tool (introduced May 2021)	An anonymous REDCap survey available publicly on the Massachusetts General Hospital Platform Trial website allowed people living with ALS to conduct an informal self-screen based on 5 key inclusion criteria for the trial. Survey outputs instructions for next steps based on someone's potential eligibility.	580 Complete survey responses submitted
		407 Respondents deemed potentially eligible
		173 Respondents deemed potentially ineligib

^aFor the first 2 years of study conduct. Data collection for this table was completed on May 18, 2023, covering the period from September 29, 2020 to December 31, 2022. Webinar metrics for YouTube views are reported annually.

Navigating Clinical Research Opportunities

- ClinicalTrials.gov <u>clinicaltrials.gov/</u>
- NEALS neals.org/als-trials/neals-affiliated
- ALS TDI Trial Navigator <u>www.als.net/als-trial-navigator/</u>

NEALS Clinical Trial Liaison

Phone: (855) 437- 4823

Email: alstrials@neals.org

- MGH <u>www.massgeneral.org/neurology/als/research/als-clinical-trials</u>
- ALS Signal (I AM ALS) www.iamals.org/get-help/als-signal-clinical-research-dashboard/
- MDA <u>www.mda.org/research/clinical-trials</u>
- ALSA <u>www.als.org/research/finding-als-research-opportunities</u>
- International Alliance of ALS/MND Associations www.als-mnd.org/support-for-pals-cals/research/understanding-als-mnd-research/

ALS & Participation in Clinical Research













A Les Turner ALS Foundation Guide for People Living with ALS

Scan to view guide in English







ELA Y PARTICIPACIÓN EN INVESTIGACIONES CLÍNICAS

Una guía hecha por la Les Turner ALS Foundation para personas viviendo con ELA

Escanea para ver la guía en español

LESTURNERALS FOUNDATION >LESTURNERALS.ORG

"Your ALS Guide"

Information about participating in various types of research

- ALS Clinical Trials
- Expanded Access
- Off Labels and Alternative Therapies
 - ALS Untangled: <u>www.alsuntangled.com/</u>
- Observational Studies
- Tissue Donation





VA ALS Website

Veterans Health Administration

- Where to go for care at VA (interactive maps)
- VA resources for ALS
- Educational videos for veterans with ALS and caregivers
- Research information







Added Considerations

What to expect in the enrollment process

- You don't always have to be a patient at the center where a study is being offered, but it's helpful to connect
 with a doctor who knows about ALS research
- Finding an ALS specialist or research center near you
 - NEALS member site finder: <u>neals.org/about/neals-member-sites</u>
 - ALS Geospatial Hub Clinic Locator: <u>als-geospatial-hub-nonprofit.hub.arcgis.com/pages/als-clinic-advisor</u>

Note about international participation

- There are important logistics to consider if looking to participate in a US-based trial while living internationally
 - International Alliance of ALS/MND Associations: www.als-mnd.org/support-for-pals-cals/research/understanding-als-mnd-research/
 - Clinical Trials in the European Union: <u>euclinicaltrials.eu</u>
 - Clinical Trials throughout Europe: <u>www.tricals.org/centres</u>







Christina Smith Communications Coordinator Northeast ALS Consortium alstrials@neals.org 855-437-4823

Your research resources in the ALS community

Michelle Redenz ACE* & Research **Access Nurse** Healey Center @ MGB mghalsresearch@mgb.org 617-726-0034

Emma Joy Goldberg Clinical Outreach Program Manager ALL ALS @ Healey Center egoldberg12@mgh.har vard.edu

Emma Allen Patient Navigator ALL ALS Study info@all-als.org 617-726-6009







Catherine Small

Judi Carey

Research Access &

ACE* Nurse

Healey Center @ MGB

mghalsresearch@mgb.org

617-724-8995

*Accelerated Centers of Enrollment

Patient Navigator HEALEY ALS Platform Trial healeyalsplatform@mgh.har vard.edu 833-425-8257



*Accelerated Centers of Enrollment

Multi-Center Clinical Research Opportunities

Investigational Medication Trials

- □ HEALEY ALS Platform Trial Phase 2-3s NCT 04297683
- ☐ Healey ALS MyMatch Trial Program
 Phase 1-2s

ACACIA trial: NCT 07047209

- Novartis VHB937 Phase 2-3 NCT 06643481
- Amylyx AMX0114 Phase 1 NCT 06665165

Biomarker & Observational Studies

- ASSESS ALL ALS
 NCT 06578195
- PREVENT ALL ALS
 NCT 06581861
- Target ALS NCT 05137665

MGH website:



Educational Webinar Opportunities

- **NEALS** <u>neals.org/people-living-with-als/educational-webinars</u>
- Les Turner ALS Foundation <u>lesturnerals.org/support-services/als-learning-series/</u>
- Everything ALS <u>www.everythingals.org/events</u>
- ALL ALS <u>www.all-als.org/webinars/</u>

Missed a webinar? View recordings online!



Patient Navigation Central resource for people living with ALS



Catherine Small

Phone: 833-425-8257 (HALT ALS)

E-mail: <u>healeyalsplatform@mgh.harvard.edu</u>

Sign up for ALS Link:




https://bit.ly/3CqGbhb

Register for webinars:



Two webinars

https://bit.ly/3r6Nd2L



Upcoming Webinars (Thurs, 5:00- 5:30pm EST):

August 14 – Ibudilast EAP Update with Björn Oskarsson, MD (Mayo Clinic Florida)

August 28 – HEALEY ALS Platform Trial Biomarker Learnings with James Berry, MD,

MPH and Eric Macklin, PhD (Mass General Hospital)